Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mohammed A. Babakkor"'
Autor:
Ibtisam A. Al Thubaiti, Mona M. AlKhawajah, Norah Al Fugham, Dema A. Alissa, Ahmed H. Al-Jedai, Yaser M. Al Malik, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Bedor A. Al-Omari, Hessa S. AlOtaibi, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, Reem F. Bunyan, Edward J. Cupler, Mohammed Hakami, Hanaa M. Kedah, Seraj Makkawi, Leena H. Saeed, Jameelah A. Saeedi, Eslam Shosha, Mohammed A. Al Jumah
Publikováno v:
Clinical and Translational Neuroscience, Vol 7, Iss 1, p 6 (2023)
This article deals with recommendations on the management of symptoms of MS and on the provision of vaccinations in patients receiving disease-modifying therapies (DMTs). Symptoms of MS, such as fatigue, depression, urinary symptoms, spasticity, impa
Externí odkaz:
https://doaj.org/article/2183e4d78c6e4b98b414b3349982ffa1
Autor:
Yaser M. Al Malik, Ibtisam A. Al Thubaiti, Maha A. AlAmmari, Norah Al Fugham, Eman N. Ali, Dema A. Alissa, Salman A. Aljarallah, Ahmed H. Al-Jedai, Maeed A. AlKathiri, Mona M. AlKhawajah, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Hessa S. Al Otaibi, Ghadah H. AlTowaijri, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, Saeed A. Bohlega, Reem F. Bunyan, Edward J. Cupler, Mohammed Hakami, Abid M. Kareem, Amr M. Khardaly, Seraj Makkawi, Leena H. Saeed, Jameelah A. Saeedi, Eslam Shosha, Mohammad A. Al Jumah
Publikováno v:
Clinical and Translational Neuroscience, Vol 6, Iss 4, p 27 (2022)
For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS patients are advised to begin treatment with a DMT shortly after diagnos
Externí odkaz:
https://doaj.org/article/2fb7ce205ae64e98a94d6195cedec570
Autor:
Mohammed A. Babakkor, Waleed M. Kattan
Publikováno v:
Saudi Journal of Health Systems Research. :1-8
Introduction: While accreditation is thought to promote healthcare quality, a literature review revealed a scarcity of studies conducted in Saudi Arabia addressing the relationship between accreditation and better care quality and healthcare organiza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed4d5da5fdbd1a152dacc4c0e0ba2f87
https://doi.org/10.1159/000529643
https://doi.org/10.1159/000529643
Autor:
Yassir M, Almatrafi, Mohammed A, Babakkor, Muhammed, Irfan, Ebaa T, Samkari, Waleed M, Alzahrani, Doaa K, Mohorjy, Sarmad, Zahoor, Muhammad T, Farooq, Hafiz M, Sajid Jehangir
Publikováno v:
Neurosciences. 27:65-70
To assess the efficacy and safety of rituximab for multiple sclerosis (MS) treatment in terms of reduction in clinical relapses, magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS) score and adverse events.This is a ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d65e7d05c73945febda583f153cf152
https://doi.org/10.17712/nsj.2022.2.20210122
https://doi.org/10.17712/nsj.2022.2.20210122
Autor:
Reem F. Bunyan, Abdulaziz M. AlAbdulSalam, Rayan G. Albarakati, Awad A. Al Harbi, Dema A. Alissa, Ahmed H. Al-Jedai, Nuha M. AlKhawajah, Yaser M. Al Malik, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Hind A. AlNajashi, Amani A. AlShehri, Ibtisam A. Althubaiti, Rumaiza H. AlYafeai, Mohammed A. Babakkor, Edward J. Cupler, Mamdouh H. Ka, Jameelah A. Saeedi, Eslam Shosha, Mohammed A. Al Jumah
Publikováno v:
Multiple sclerosis and related disorders. 66
Multiple sclerosis (MS) most commonly presents in young adults, although 3-5% of patients develop MS prior to the age of 18 years. The new and comprehensive consensus for the management of MS in Saudi Arabia includes recommendations for the managemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2687077e799d1d91097bb7a7634cb711
https://pubmed.ncbi.nlm.nih.gov/35908447
https://pubmed.ncbi.nlm.nih.gov/35908447